Combination of Benazepril Plus Hydrochlorothiazide in Chinese Patients With Mild to Moderate Essential Hypertension

Novartis

Status and phase: Completed; Phase 3

Conditions: Hypertension

Treatments: Drug: Benazepril plus hydrochlorothiazide

Study type: Interventional

Funder types: Industry

Identifiers

NCT00367094

CLHT344ACN01

Details and patient eligibility

About

This study will evaluate efficacy and safety data for benazepril/hydrochlorothiazide in adult Chinese patients with mild to moderate essential hypertension. Patients whose blood pressure is not adequately controlled with benazepril monotherapy during a 4 week run-in period will be randomly allocated to double blind treatment over 8 weeks with either a combination of benazepril/hydrochlorothiazide per day or continuation of benazepril per day.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or female patients, age 18 or older
• Given informed consent
• Diagnosed as having mild to moderate essential hypertension

Exclusion criteria

• Severe hypertension
• Significant preexisting cardiovascular and cerebrovascular disease
• Diabetes mellitus type 1 or poorly controlled diabetes mellitus type II
• Advanced renal impairment

Other protocol-defined inclusion/exclusion criteria may apply.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind